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Abstract
Both L-arginine supplementation and deprivation influence cell proliferation. The effect of high
doses on tumours is determined by the optical configuration: L-arginine is stimulatory, D-arginine
inhibitory. Arginine-rich hexapeptides inhibited tumour growth. Deprivation of L-arginine from cell
cultures enhanced apoptosis. The pro-apoptotic action of NO synthase inhibitors, like NG-
monomethyl-L-arginine, is manifested through inhibition of the arginase pathway. NG-
hydroxymethyl-L-arginines caused apoptosis in cell cultures and inhibited the growth of various
transplantable mouse tumours. These diverse biological activities become manifest through
formaldehyde (HCHO) because guanidine group of L-arginine in free and bound form can react
rapidly with endogenous HCHO, forming NG-hydroxymethylated derivatives. L-arginine is a
HCHO capturer, carrier and donor molecule in biological systems. The role of formaldehyde
generated during metabolism of NG-methylated and hydroxymethylated arginines in cell
proliferation and death can be shown. The supposedly anti-apoptotic homozygous Arg 72-p53
genotype may increase susceptibility of some cancers. The diverse biological effects of L-arginine
and its methylated derivatives call for further careful studies on their possible application in
chemoprevention and cancer therapy.
Introduction
L-arginine (Arg), an essential amino acid, is required for
normal growth of microbes, plants and animals. Depriva-
tion of this amino acid from the culture medium or other
sources of nutrition causes serious disturbances in cellular
and organ function leading to total destruction. On the
other hand, excessive doses of Arg also influence cell func-
tion, including cell death and cell proliferation. Substan-
tial information has been obtained in the past decades on
the role of Arg in tumour growth and in tumour therapy.
Effect of Arg deprivation and supplementation 
on tumour cell proliferation
Arg, an essential amino acid, is required to maintain nor-
mal metabolism and proliferation of cells in culture [1].
Attempts to influence tumour cell proliferation by chang-
es in amino acid balance were based on such observa-
tions. The role of the enzyme arginase, which decreases
the amount of Arg, was thoroughly investigated in this re-
spect and also used in the therapy of human tumours [2].
According to Umeda et al.[3], the proliferation of both
HeLa cells in vitro and rat Novikoff hepatoma in vivo
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could be decreased by arginase, causing relative Arg defi-
ciency. Otsuka [4] has shown that an enzyme, very similar
to arginase inhibits DNA synthesis in normal rat liver. The
proliferation promoting activity of L-Arg is also under-
scored by the fact, that Arg is converted by arginase to L-
ornithine, which is the precursor of various polyamines
essential for cell proliferation [5]. Tanaka et al.[6] have
demonstrated the death of 3T3 cells after Arg deprivation.
Wheatley et al.[7–10] analysed the effect of deprivation of
eleven essential amino acids on several tumour cell lines
and found that apoptotic-like cell death occurs as a conse-
quence of this manipulation. The cell lines died consider-
ably more quickly during Arg deprivation than in the
absence of any other essential amino acids. Moreover,
when co-cultures of normal and tumour cells were de-
prived of Arg the normal cells survived and the tumour
cells died. According to these observations, Arg depriva-
tion causes selective death of cultured malignant cells.
Lamb and Wheatley [11] have also shown, that Arg depri-
vation most probably impairs the control of DNA synthe-
sis at the G1 checkpoint, which normally inhibits its
initiation of DNA synthesis under unfavourable condi-
tions.
Arg imbalance was also produced by excess of Arg supple-
mentation in the diet. Brittenden et al.[13] Suggested a
possible therapeutic effect of Arg-rich diet in malignant
disease, in combination with anti-cancer chemotherapy.
Ogilvie et al.[14] found that excess Arg combined with
doxorubicin chemotherapy extended disease-free interval
and survival time of dogs with lymphoma. According to
the studies of Hester and Fee [15] on squamous cell carci-
noma in the CH3/KM mouse the mechanism of action of
high amounts of Arg may be the stimulation of host im-
mune surveillance. However, Robinson et al.[16] found
that Morris hepatoma-bearing rats fed with Arg-rich diet
did not show any alteration in tumour growth or cytokine
production. The role of Arg in carcinogenesis has been
challenged by the experiments of Weinberger et al.[17]
who found that high doses of Arg glutamate decreased the
carcinogenic activity of various acetamine-derivatives in
rats.
Interesting data were reported on Arg-induced apoptosis
of pancreatic acinar cells both in vitro and in vivo [18]
providing a model of acute pancreatitis. The possible ther-
apeutic use of Arg against pancreatic acinic cell carcinoma
has not been examined yet.
Arg-rich hexapeptides were identified from peptide librar-
ies that inhibit the interaction of vascular endothelial
growth factor to its receptor. These hexapeptides inhibit
the proliferation of human umbilical vein endothelial
cells and also block the angiogenesis induced by vascular
endothelial growth factor in vivo, in the chick chorioal-
lantoic membrane and in the rabbit cornea. One of the
hexapeptides blocks the growth and formation of metas-
tases of HM7 human colon carcinoma cells in nude mice
[19]. These results may serve as leads for development of
anticancer drugs.
Arg imbalance was established in our early in vivo experi-
ments [20]. High doses of L-Arg, D-Arg and DL-Arg (400–
500–1000 mg/kg body weight intraperitoneally or orally)
were administered to Wistar rats bearing subcutaneous
Yoshida's sarcoma or to Swiss mice bearing subcutaneous
Ehrlich carcinoma for 9–15 days (table 1). D-Arg inhibit-
ed the growth of Yoshida's sarcoma significantly (50%, p
< 0.05), when applied in a daily dose of 500 mg/kg, orally.
Intraperitoneal administration of the same dose to Ehr-
lich carcinoma bearing mice resulted in a 20%, statistical-
ly not significant, inhibition.
L-Arg, however, enhanced the growth of Yoshida's sarco-
ma, when given intraperitoneally or orally in a dose of
400 mg/kg. The same tendency, namely significant (40%)
enhancement was seen after intraperitoneal treatment
(400 mg/kg) of Ehrlich carcinoma bearing mice.
Table 1: Effect of D-Arg, L-Arg and DL-Arg on the growth of transplantable animal tumours






D-Arg1 Yoshida 6 6 500 p.o. 12 50 p < 0.05
D-Arg 1 Ehrlich s.c. 10 10 500 i.p. 10 20 p < 0.1
L-Arg3 Yoshida 10 10 400 i.p. 10 -40 Enhancement p < 0.05
L-Arg3 Yoshida 10 10 400 p.o. 9 -30 Enhancement p < 0.1
L-Arg2 Ehrlich s.c. 10 10 500 i.p. 12 -40 Enhancement p < 0.05
DL-Arg3 Ehrlich s.c. 10 10 500 i.p. 12 - -
1Serva (USA), 2Ajinomoto (Japan), 3Reanal (Hungary) Animals were sacrificed 24 hours after the last treatment and tumour weight was measured. 
Inhibition or enhancement is given as per cent of the control tumours. Abbreviations:i. p. – intraperitoneal; p. o. – peroral; s. c. – subcutaneous; Arg 
– arginineCancer Cell International 2001, 1 http://www.biomedcentral.com/1475-2867/1/3
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Intraperitoneal application of 500 mg/kg DL-Arg to mice,
inoculated with Ehrlich carcinoma had neither inhibitory
nor enhancing effect on tumour growth. Various path-
ways of metabolism of this amino acid may explain the
mode of action of Arg imbalance. Among these methyla-
tion and hydroxymethylation appear to be of special im-
portance.
Effect of methylated, hydroxy and hydroxymeth-
ylated Arg on cell death and proliferation
Arg is a highly reactive compound, both as a free amino
acid and as a constituent of a protein. The structure of pro-
teins can be altered by specific enzymatic modification of
the side chains. One of these protein-modifying reactions
is methylation, resulting in the addition of methyl groups
to the guanidine residues of Arg. Methylated Arg also oc-
cur in free form, possibly resulting from enzymatic hy-
drolysis of methylated proteins in vivo (fig. 1).
Mono-di- and trimethyl Arg, hydroxymethyl Arg, N-ome-
ga-hydroxy L-Arg, N-nitro-L-Arg methyl ester, Nitro-Arg
were studied regarding the possible effect on cell death
and cell proliferation of these compounds.
Tyihák et al.[21] demonstrated that monomethyl Arg and
dimethyl-Arg inhibit significantly the growth of tobacco
tissue cultures in concentrations of 10–100 ppm in agar
nutrient medium, NG-methylated Arg added to agar-me-
dium also significantly inhibited the growth of the roots
of lettuce seedlings. Further investigations along this line
carried out by Szende et al.[22] have shown that NG-hy-
droxymethyl Arg inhibited dose-dependently and signifi-
cantly the proliferation of HT-29 human colon carcinoma
cells, P-388 mouse lymphoma cells and PC-3 human
prostate carcinoma as well as K-562 human erythroleu-
kaemia cells in culture. The cells of the treated cultures
showed morphological signs of apoptosis in a high per-
centage. In our in vivo experiments [20] hydroxymethyl-
ated Arg was administered to Swiss mice inoculated with
Ehrlich ascites tumour. The daily dose of NG-hydroxyme-
thyl Arg was 400 mg/kg intraperitoneally, based on previ-
ous acute toxicity studies. After 10 days of NG-
hydroxymethylated Arg treatment complete inhibition of
the growth of Ehrlich ascites tumour was observed.
C57B1 mice, inoculated with Lewis lung tumour intra-
muscularly and made tumour free by amputation of the
tumorous leg 10 days after tumour transplantation, were
treated for seven days with 400 mg/kg NG-hydroxymethyl
Arg, daily, intraperitoneally. The treatment started 24
hours after amputation. The animals were sacrificed on
the 8th day after starting the treatment. Lung metastasis
number and volume were determined. The average metas-
tasis number in the treated animals was 27, in the controls
54. The average volume of the lung nodules was 34 mm3
in the treated and 50 in the control mice.
The anti-proliferative and apoptosis-inducing effect of
Arg-derivatives was confirmed by the studies of Singh et
al.[5] who found that N-omega-hydroxy-L-Arg inhibited
the proliferation of the high-arginase-expressing MDH-
MB-468 cells and induced apoptosis after 48 hours. It has
also been shown by Washo-Stultz et al.[23] that N-nitro-
Arg methyl ester sensitised cells to apoptosis induced by
sodium deoxycholate.
L-Arg, nitro-Arg and methyl-Arg have been found to in-
duce increase in cytosolic Ca concentration in cultured
NIT-1 cells [24], leading to depolarisation of the plasma
membrane potential, a phenomenon common during the
process of apoptosis.
NG-methyl-L-Arg [25] N-nitro-L-Arg methyl ester [23], N-
hydroxy-L-Arg [5] and L-NG-methyl-Arg [26] all proved to
be inhibitors of nitric oxide synthase. Nitric oxide syn-
thase converts L-Arg to produce NO, which "Janus-faced"
compound certainly may influence both cell proliferation
and cell death.
Role of formaldehyde in the mechanism of ac-
tion of methylated arginines
Another possible mode of action of methylated and hy-
droxymethylated Arg can be deduced from the fact that
these molecules are formaldehyde generators. It has been
demonstrated by Hullán et al.[27] that NG-hydroxyme-
thyl Arg as a biomolecule is one of the compounds that
are responsible for the endogenous formaldehyde level.
The guanidine group of L-Arg can bind one, two or three
molecules of CH2O and in the reaction mono-, di- and tri-
hydroxymethylated Arg derivatives are formed. This proc-
ess is catalysed by the enzyme transmethylase [28]. The
hydroxymethylated derivatives of Arg are relatively stable
compounds. Arg is suitable to carry the endogenous
CH2O in form of hydroxymethyl group in biological sys-
tems. The hydroxymethyl groups are attached to the gua-
nidine group by reversible bindings [29]. Although little is
known about the demethylation of NG-methylated Arg,
NG-hydroxymethyl-L-Arg generates a direct CH2O-yield-
ing activity, which may be responsible for its apoptotic ef-
fect [22,30]. It has also been shown in our recent
experiments [31] that the administration of analytically
pure formaldehyde to cell cultures causes dose depend-
ently apoptosis (1–10 µg/ml) or stimulation of DNA syn-
thesis and cell proliferation (0.1–0.01 µg/ml). The
calculated quantity of formaldehyde released by demeth-
ylation processes from hydroxymethyl Arg is in the above
mentioned range and the formaldehyde-mediated biolog-
ical action of this compound has to be taken into consid-
eration.Cancer Cell International 2001, 1 http://www.biomedcentral.com/1475-2867/1/3
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Lysine-arginine antagonism
The lysine-arginine antagonism widely shown in nature is
also represented in apoptosis resistant cell lines that con-
tain A-to G alteration is the death domain, encoding L-ar-
ginine instead of L-lysine in codon 441 [32].
Arg 72-p53 genotype and cancer
Over-representation of the homozygous Arg 72-p53 gen-
otype in cervical carcinoma patients has been reported
[33]. However, Tachezy et al.[34] did not find increased
risk for human papilloma virus-associated cervical tu-
mour development associated with Arg 72-p53.
Conclusions
Although data in the literature are pointing to the anti
proliferative effect of both Arg depletion and supplemen-
tation, Arg proved to be essential for tumour cell growth.
This observation raises the question, whether decreasing
the concentration of Arg in nutrients and consequently in
blood serum or the administration of D-arginine may
lead to retardation of tumour growth in humans, too. Arg,
because of its strong basic guanidine group, plays an im-
portant role in molecular interactions in biological sys-
tems, such as interaction between Arg and formaldehyde,
both of which are normal components of cells and biolog-
ical fluids. As a result, hydroxymethyl derivatives of Arg
are formed. These compounds may be the source of for-
maldehyde generation. Arg may be considered a formal-
dehyde capturer, carrier and generator molecule. These
functions may also play role in the biological activity of
Arg and its methylated and hydroxymethylated deriva-
tives. An interesting therapeutic possibility worthy of fur-
ther investigation may be the administration of
methylated and hydroxymethylated Arg in order to induce
tumour cell death or to prevent tumour cell proliferation.
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